(News Bulletin 247) – Invest Securities confirms its buy rating on Transgene stock, with a price target reduced from 5.7 to 5.4 euros.
The analyst firm reports that the company has outlined a 2023 plan punctuated with several catalysts that should reinforce the early results announced in most of their clinical programs.
In particular, two clinical trials potentially opening the way to registration are planned in the short term in the therapeutic vaccine franchise.
“2023 should be a year of consolidation, with 2024 shaping up to be the year of proof of concept,” says the analyst.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
